A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) - V940-001 - Merck Sharp & Dohme LLCSee more
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) - MK-3475-02B - Merck Sharp & Dohme LLCSee more
Liposarcoma
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma - Brightline-4 - Boehringer IngelheimSee more
